161 related articles for article (PubMed ID: 38170760)
1. Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN.
Davidson MB; Kennedy JA; Capo-Chichi JM; Shi Y; Xu W; Cheung V; Arruda A; Bankar A; Richard-Carpentier G; Chan S; Maze D; Minden MD; Schimmer AD; Schuh AC; Sibai H; Yee K; Tierens A; Viswabandya A; Gupta V
Blood Adv; 2024 Mar; 8(5):1281-1294. PubMed ID: 38170760
[TBL] [Abstract][Full Text] [Related]
2. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
3. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
4. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
[TBL] [Abstract][Full Text] [Related]
6. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
Benitez LL; Perissinotti AJ; Rausch CR; Klaus J; Clark SM; Filtz M; Ratermann K; Treptow C; Griffin S; Olson M; Crain M; Kadia T; Pettit K; Burke PW; Bixby DL; Marini BL
Leuk Lymphoma; 2021 Sep; 62(9):2184-2192. PubMed ID: 33830856
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms.
Castillo Tokumori F; Al Ali N; Chan O; Sallman D; Yun S; Sweet K; Padron E; Lancet J; Komrokji R; Kuykendall AT
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e521-e525. PubMed ID: 35241387
[TBL] [Abstract][Full Text] [Related]
8. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Badar T; Kantarjian HM; Ravandi F; Jabbour E; Borthakur G; Cortes JE; Pemmaraju N; Pierce SR; Newberry KJ; Daver N; Verstovsek S
Leuk Res; 2015 Sep; 39(9):950-6. PubMed ID: 26183878
[TBL] [Abstract][Full Text] [Related]
10. Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
Chauvet P; Nibourel O; Berthon C; Goursaud L; Carpentier B; Lionne-Huyghe P; Wemeau M; Quesnel B
Leuk Res; 2022 Jul; 118():106871. PubMed ID: 35633618
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and predictors of survival in blast phase myeloproliferative neoplasms.
Lancman G; Brunner A; Hoffman R; Mascarenhas J; Hobbs G
Leuk Res; 2018 Jul; 70():49-55. PubMed ID: 29807273
[TBL] [Abstract][Full Text] [Related]
12. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
Gupta V; Kim S; Hu ZH; Liu Y; Aljurf M; Bacher U; Beitinjaneh A; Cahn JY; Cerny J; Copelan E; Gadalla SM; Gale RP; Ganguly S; George B; Gerds AT; Gergis U; Hamilton BK; Hashmi S; Hildebrandt GC; Kamble RT; Kindwall-Keller T; Lazarus HM; Liesveld JL; Litzow M; Maziarz RT; Nishihori T; Olsson RF; Rizzieri D; Savani BN; Seo S; Solh M; Szer J; Verdonck LF; Wirk B; Woolfrey A; Yared JA; Alyea EP; Popat UR; Sobecks RM; Scott BL; Nakamura R; Saber W
Blood Adv; 2020 Oct; 4(19):4748-4757. PubMed ID: 33007075
[TBL] [Abstract][Full Text] [Related]
13. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
Wang H; Mao L; Yang M; Qian P; Lu H; Tong H; Xie W; Zhou D; Huang X; Wang Y; Xu G; Lu Y; Wei J; Mai W; Ye X; Meng H; Shen Y; Huang J; Yu W; Sun J; Sheng J; Yan X; Jin J; Zhu HH
Lancet Haematol; 2022 Jun; 9(6):e415-e424. PubMed ID: 35512726
[TBL] [Abstract][Full Text] [Related]
15. The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.
McNamara CJ; Panzarella T; Kennedy JA; Arruda A; Claudio JO; Daher-Reyes G; Ho J; Siddiq N; Devlin R; Tsui H; Su J; Stockley T; Sukhai M; Kanwar N; Chan S; Maze D; Schimmer A; Schuh A; Sibai H; Viswabandya A; Yee K; Minden MD; Kamel-Reid S; Gupta V
Blood Adv; 2018 Oct; 2(20):2658-2671. PubMed ID: 30327374
[TBL] [Abstract][Full Text] [Related]
16. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
Bewersdorf JP; Rampal RK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Cherington C; Slack JL; Leis J; Adams RH; Reeder CB; Mikhael JR; Camoriano J; Noel P; Fauble V; Betcher J; Higgins MS; Gillette-Kent G; Tremblay LD; Peterson ME; Olsen JJ; Tibes R; Mesa RA
Leuk Res; 2012 Sep; 36(9):1147-51. PubMed ID: 22578777
[TBL] [Abstract][Full Text] [Related]
18. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
[TBL] [Abstract][Full Text] [Related]
20. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.
Estey E; Thall PF; Kantarjian H; O'Brien S; Koller CA; Beran M; Gutterman J; Deisseroth A; Keating M
Blood; 1992 May; 79(9):2246-55. PubMed ID: 1571541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
